FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2787370436> ?p ?o ?g. }

• W2787370436 endingPage "e116" @default.
• W2787370436 startingPage "e109" @default.
• W2787370436 abstract "Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published data on either regimen alone. Methods In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients aged 18 years or older with relapsed or refractory mantle cell lymphoma who had previously been treated with at least one rituximab-containing regimen, an Eastern Cooperative Oncology Group performance status score of 0–3, and at least one site of measurable disease, and who met criteria for several laboratory-assessed parameters. Treatment was divided into an induction phase of 12 cycles of 28 days with all three drugs and a maintenance phase with ibrutinib and rituximab only (cycle duration 56 days), given until disease progression or unacceptable toxicity. In the induction phase, patients received intravenous (375 mg/m2) or subcutaneous (1400 mg) rituximab once a week during cycle 1 and then once every 8 weeks. Oral ibrutinib (560 mg once a day) was given to patients every day in the cycle, whereas oral lenalidomide (15 mg once a day) was given on days 1–21. The primary endpoint was overall response assessed in the intention-to-treat population according to Lugano criteria. Safety analysis included all patients who received the treatment, irrespective of eligibility or duration of treatment. The trial is ongoing, but is no longer accruing patients, and is registered with ClinicalTrials.gov, number NCT02460276. Findings Between April 30, 2015, and June 1, 2016, we enrolled 50 patients with relapsed or refractory mantle cell lymphoma at ten centres in Sweden, Finland, Norway, and Denmark. At a median follow-up of 17·8 months (IQR 14·7–20·9), 38 (76%, 95% CI 63–86) patients had an overall response, including 28 (56%, 42–69) patients who had a complete response and ten (20%, 11–33) who had a partial response. The most common grade 3–4 adverse events were neutropenia (in 19 [38%] of 50 patients), infections (in 11 [22%] patients), and cutaneous toxicity (in seven [14%] patients). There were three treatment-related deaths during the study, two due to sepsis and one due to embolic stroke. Interpretation Our results provide preliminary evidence that the triplet combination of ibrutinib, lenalidomide, and rituximab is an active regimen in patients with relapsed or refractory mantle cell lymphoma, and should be evaluated in a prospective randomised controlled trial. Funding Janssen and Celgene." @default.
• W2787370436 created "2018-02-23" @default.
• W2787370436 creator A5008481807 @default.
• W2787370436 creator A5010381524 @default.
• W2787370436 creator A5013096706 @default.
• W2787370436 creator A5028743667 @default.
• W2787370436 creator A5031608512 @default.
• W2787370436 creator A5033781914 @default.
• W2787370436 creator A5047869667 @default.
• W2787370436 creator A5053045551 @default.
• W2787370436 creator A5054258973 @default.
• W2787370436 creator A5057884204 @default.
• W2787370436 creator A5058855375 @default.
• W2787370436 creator A5067329171 @default.
• W2787370436 creator A5082053412 @default.
• W2787370436 creator A5090605318 @default.
• W2787370436 date "2018-03-01" @default.
• W2787370436 modified "2023-10-10" @default.
• W2787370436 title "Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial" @default.
• W2787370436 cites W1192491316 @default.
• W2787370436 cites W1712566393 @default.
• W2787370436 cites W2009937603 @default.
• W2787370436 cites W2065464657 @default.
• W2787370436 cites W2071899049 @default.
• W2787370436 cites W2095491662 @default.
• W2787370436 cites W2098002594 @default.
• W2787370436 cites W2100608938 @default.
• W2787370436 cites W2119147717 @default.
• W2787370436 cites W2124235514 @default.
• W2787370436 cites W2124432094 @default.
• W2787370436 cites W2131823788 @default.
• W2787370436 cites W2142604595 @default.
• W2787370436 cites W2145785161 @default.
• W2787370436 cites W2154066874 @default.
• W2787370436 cites W2184668473 @default.
• W2787370436 cites W2187899653 @default.
• W2787370436 cites W2190884983 @default.
• W2787370436 cites W2195033221 @default.
• W2787370436 cites W2287519522 @default.
• W2787370436 cites W2528264979 @default.
• W2787370436 cites W2582696216 @default.
• W2787370436 cites W2749289906 @default.
• W2787370436 doi "https://doi.org/10.1016/s2352-3026(18)30018-8" @default.
• W2787370436 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29396091" @default.
• W2787370436 hasPublicationYear "2018" @default.
• W2787370436 type Work @default.
• W2787370436 sameAs 2787370436 @default.
• W2787370436 citedByCount "106" @default.
• W2787370436 countsByYear W27873704362018 @default.
• W2787370436 countsByYear W27873704362019 @default.
• W2787370436 countsByYear W27873704362020 @default.
• W2787370436 countsByYear W27873704362021 @default.
• W2787370436 countsByYear W27873704362022 @default.
• W2787370436 countsByYear W27873704362023 @default.
• W2787370436 crossrefType "journal-article" @default.
• W2787370436 hasAuthorship W2787370436A5008481807 @default.
• W2787370436 hasAuthorship W2787370436A5010381524 @default.
• W2787370436 hasAuthorship W2787370436A5013096706 @default.
• W2787370436 hasAuthorship W2787370436A5028743667 @default.
• W2787370436 hasAuthorship W2787370436A5031608512 @default.
• W2787370436 hasAuthorship W2787370436A5033781914 @default.
• W2787370436 hasAuthorship W2787370436A5047869667 @default.
• W2787370436 hasAuthorship W2787370436A5053045551 @default.
• W2787370436 hasAuthorship W2787370436A5054258973 @default.
• W2787370436 hasAuthorship W2787370436A5057884204 @default.
• W2787370436 hasAuthorship W2787370436A5058855375 @default.
• W2787370436 hasAuthorship W2787370436A5067329171 @default.
• W2787370436 hasAuthorship W2787370436A5082053412 @default.
• W2787370436 hasAuthorship W2787370436A5090605318 @default.
• W2787370436 hasBestOaLocation W27873704362 @default.
• W2787370436 hasConcept C121332964 @default.
• W2787370436 hasConcept C126322002 @default.
• W2787370436 hasConcept C141071460 @default.
• W2787370436 hasConcept C142424586 @default.
• W2787370436 hasConcept C143998085 @default.
• W2787370436 hasConcept C203092338 @default.
• W2787370436 hasConcept C2776063141 @default.
• W2787370436 hasConcept C2776364478 @default.
• W2787370436 hasConcept C2776694085 @default.
• W2787370436 hasConcept C2777063308 @default.
• W2787370436 hasConcept C2777525834 @default.
• W2787370436 hasConcept C2777938653 @default.
• W2787370436 hasConcept C2778461978 @default.
• W2787370436 hasConcept C2778850193 @default.
• W2787370436 hasConcept C2779338263 @default.
• W2787370436 hasConcept C2779878957 @default.
• W2787370436 hasConcept C2780653079 @default.
• W2787370436 hasConcept C2781413609 @default.
• W2787370436 hasConcept C2908647359 @default.
• W2787370436 hasConcept C31760486 @default.
• W2787370436 hasConcept C535046627 @default.
• W2787370436 hasConcept C71924100 @default.
• W2787370436 hasConcept C87355193 @default.
• W2787370436 hasConcept C99454951 @default.
• W2787370436 hasConceptScore W2787370436C121332964 @default.
• W2787370436 hasConceptScore W2787370436C126322002 @default.
• W2787370436 hasConceptScore W2787370436C141071460 @default.
• W2787370436 hasConceptScore W2787370436C142424586 @default.

• next